Announcement PDF ASX Announcement 19/10/2021 MDMA analogue development milestone Highlights: ● First batch of MDMA analogues shipped for CNS activity screening ● Leading European pharmacological screening company, Eurofins (EPA:ERF, market cap US$21B) engaged to commence screening for Emyria’s exclusive library of MDMA analogues ● Eurofins will perform a series of targeted CNS screens to support the identification and development of lead compounds ● Data collected will also support further patent applications ● Eurofins (EPA:ERF) is a global specialist in testing and analytical services to support discovery pharmacology Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, is pleased to select Eurofins - the world leader in pharmaceutical products testing - to lead an extensive compound screening program for the unique MDMA-analogue library. The analysis plan developed with Eurofins will provide UWA and Emyria insights to inform lead compound identification and further development. The data received will also strengthen the intellectual property portfolio for the library. Emyria’s Managing Director, Dr. Michael Winlo, said: “We are pleased to be working with global leader, Eurofins to screen our first batch of novel MDMA-analogues after successfully completing purity and stability testing at UWA. Eurofins are experts in supporting a complete drug development cycle for new chemical entities and they routinely work with the largest and most innovative biopharmaceutical companies in the world. The analysis we have prepared will help Emyria select the most promising drug candidates within the MDMA analogue library for further preclinical evaluation and development.” 1 The MDMA analogy library Emyria recently secured exclusive rights to a library of more than 100 novel MDMA analogues from the University of Western Australia creating a unique drug-discovery pipeline. (See ASX announcement 05 Aug 2021) The library of compounds has been compiled by the highly regarded research group led by medicinal chemist, Dr. Matt Piggott, who has been working with MDMA analogues, and exploring their therapeutic potential, for more than 10 years Emyria aims to screen and expand the existing library in order to identify families of patentable compounds with the greatest promise as new psychedelic-assisted therapies and treatments for other neurological disorders Alongside screening, Emyria is leading a global patent strategy, already underway, as well as further clinical development and commercialisation of this unexplored research space. The program has the potential to result in the commercialisation of multiple, novel, CNS-active compounds to help treat patients with major unmet needs. This announcement has been approved and authorised for release by the Board of Emyria Limited. For further information: Dr. Michael Winlo Managing Director 1300 436 363 mwinlo@emyria.com Lexi O’Halloran Media/Investor Relations + 61 (0) 404 577 076 Andrew Williams Media Relations +61 (0) 412 614 125 lexi@janemorganmanagement.com.au andreww@profilemedia.com.au About Emyria (www.emyria.com) Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au) Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs. 2 About Eurofins Scientific (www.eurofins.com) Eurofins Scientific through its subsidiaries is the world leader in pharmaceutical products testing. It is also one of the global independent market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty esoteric and molecular clinical diagnostic testing in Europe and the USA. With 55,000 staff across a network of more than 1,000 independent companies in over 50 countries and operating 900 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostics. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. 3